
    
      Evaluation indications include bone marrow morphology,hematopoietic recovery (neutrophil and
      platelet), 100-day transplantation-related mortality (TRM), donor chimerism, acute GVHD,
      chronic GVHD, disease free survival (DFS), and overall survival (OS). The cut-time of the
      follow-up was Oct, 2013. DFS was defined as the time between the date of transplantation to
      the death or relapse. OS was defined as the time from diagnosis to death or to the last date
      of follow-up until Oct. 2013.
    
  